Te Whatu Ora – Southern Commercial Agreement Completed

Company Announcement
13
th
January 2023

TE WHATU ORA – SOUTHERN COMMERCIAL AGREEMENT COMPLETED
DUNEDIN, New Zealand – Pacific Edge (NZX, ASX PEB)

On the 21st July 2022, Pacific Edge announced that it had substantially completed a commercial agreement with
Te Whatu Ora – Southern for the use of its non-invasive Cxbladder genomic biomarker tests.

After advising the market that the signing of the Contract has been delayed on the 22nd September 2022, Pacific
Edge can now confirm the signed executed agreement has been received.

Reference to original release – 21 July 2022: https://www.nzx.com/announcements/395682
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

For more information:
Investors Media
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: +6422 032 1263


OVERVIEW www.pacificedgex.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and
commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of
recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through
its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder: www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder
evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection,
surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing
and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the
clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists
in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the
test online.